Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection [Phase 3]

View source ↗

Summary

Phase 3 trial update for ABT-493/ABT-530 evaluating efficacy and safety in genotype 1 hepatitis C infection; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ABT-493/ABT-530 (glecaprevir/pibrentasvir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C, Hepatitis C Virus | Phase 3 | Status: COMPLETED | Results posted: 2017-09-14